Table 2.
Right ventricular global (average) strain values stratified by diagnostic groupd
| Overt ARVD/C (N = 39) | Preclinical ARVD/C (N = 40) | Controls (N = 31) |
P-Valuec | |
|---|---|---|---|---|
| MEDIS | −17.6 ± 6.3ab | −21.8 ± 4.6 | −21.4 ± 5.5 | 0.001 |
| TOMTEC | −14.3 ± 7.1ab | −17.7 ± 6.6 | −17.8 ± 5.6 | 0.057 |
| MTT | −19.3 ± 6.2ab | −26.2 ± 5.0 | −27.7 ± 5.5 | <0.001 |
| CIRCLE | −21.3 ± 5.3 a | −22.9 ± 3.7 | −23.7 ± 2.3 | 0.065 |
a Statistical significant difference compared to control subjects; b = Statistical significant difference compared to preclinical subjects; c = Trend between overt ARVD/C patients, preclinical ARVD/C and control subjects (OneWay ANOVA). Abbreviations: ARVD/C = Arrhythmogenic Right Ventricular Dysplasia/ Cardiomyopathy; MTT = Multimodality Tissue Tracking; N = number of subjects
d Segments included based on adequate tracking quality: 365/438, 429/468, and 328/360 segments in overt ARVD/C, preclinical ARVD/C and control subjects respectively